Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial
暂无分享,去创建一个
Dylan L. Steen | Marc P. Bonaca | E. Braunwald | C. Cannon | H. White | W. Weaver | P. Serruys | S. Murphy | C. Bode | J. Hochman | A. Maggioni | M. O’Donoghue | S. Wiviott | P. Steg | R. Davies | S. Crugnale | M. Lukas | K. Im | J. Shannon | E. Tarka | David Watson
[1] P. Pais,et al. Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.
[2] A. Postle,et al. Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial , 2014, PloS one.
[3] E. Braunwald,et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. , 2011, American heart journal.
[4] L. Cardon,et al. Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean Males , 2011, PloS one.
[5] ZiadMallat,et al. Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease , 2010 .
[6] I. Verde,et al. [Lipoprotein-associated phospholipase A(2) and stroke]. , 2009, Revista de neurologia.
[7] Ping Zhang,et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.
[8] Frits Mastik,et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.
[9] M. Hanefeld,et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.
[10] J. Alpert,et al. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .
[11] S. Solomon,et al. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[12] A. Siegbahn,et al. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. , 2007, European heart journal.
[13] A. Moss,et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. , 2006, Clinical chemistry.
[14] H. Brenner,et al. Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[15] M. Sabatine,et al. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.
[16] U. Ikeda,et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. , 2002, Atherosclerosis.
[17] M. Yen,et al. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. , 2000, Atherosclerosis.
[18] T. Häkkinen,et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[19] D. Tew,et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.